is there a lawsuit against tirzepatide Eli Lilly sues Mochi Health and others for 'deceptive' marketing Zepbound Lawsuit [2026] | Gastrointestinal

Our study addresses an important and practical question: whether GLP-1 receptor agonists appear safe in this population and whether their use is associated with meaningful clinical outcomes such as steroid dependence and hospitalization. The researchers used the TriNetX research network to identify adults with Crohns disease and overweight or obesity who either started a GLP-1 receptor agonist or had no exposure

Emerging options in immune-mediated hearing loss

Collagen supplementation supports healthy collagen metabolism and overall structural integrity

Pored ljudi koji su primali najveu dozu retatrutida (12 mg), koji su u proseku gubili 24 odsto teine tokom 48 nedelja, a vie od jedne etvrtine tih uesnika je doivelo gubitak teine od najmanje 30%

Half the participants were randomly assigned to the Setria Performance Blend [SPB

Can the color of the medication change over time